INT76091

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1998
Last Reported 2010
Negated 1
Speculated 3
Reported most in Body
Documents 48
Total Number 52
Disease Relevance 18.40
Pain Relevance 7.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (NOS3) aging (NOS3) Golgi apparatus (NOS3)
mitochondrion organization (NOS3) cytoplasm (NOS3) cytosol (NOS3)
Anatomy Link Frequency
platelets 3
endothelial cell 3
saphenous vein 2
nerve 2
reticulum 2
NOS3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 268 99.98 Very High Very High Very High
agonist 630 99.82 Very High Very High Very High
aspirin 93 99.70 Very High Very High Very High
COX-2 inhibitor 28 99.52 Very High Very High Very High
antagonist 35 99.44 Very High Very High Very High
Serotonin 7 98.80 Very High Very High Very High
opiate 4 98.80 Very High Very High Very High
bradykinin 45 97.40 Very High Very High Very High
Morphine 15 96.62 Very High Very High Very High
Pain 181 95.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 273 99.98 Very High Very High Very High
Targeted Disruption 29 99.74 Very High Very High Very High
Increased Venous Pressure Under Development 377 98.84 Very High Very High Very High
Calciphylaxis 41 98.74 Very High Very High Very High
Disease 260 98.56 Very High Very High Very High
Diabetes Mellitus 353 98.28 Very High Very High Very High
Prediabetic State 14 97.64 Very High Very High Very High
Coronary Heart Disease 27 97.28 Very High Very High Very High
Metabolic Syndrome 40 97.12 Very High Very High Very High
Insulin Resistance 62 96.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
At all concentrations tested, aspirin increased the activity of NOS-3 from platelets.
Positive_regulation (increased) of NOS-3 in platelets
1) Confidence 0.61 Published 2009 Journal Cardiovasc. Res. Section Body Doc Link 19377066 Disease Relevance 0 Pain Relevance 0
Activation of human ECs, obtained from the saphenous vein, with morphine- or anandamide-stimulated NO release (35 nM and 28 nM, respectively) that peaked within 5 min and returned to basal levels within 10 min of agonist stimulation, consistent with constitutive NO synthase (cNOS) activation.
Positive_regulation (activation) of cNOS in saphenous vein associated with agonist and morphine
2) Confidence 0.60 Published 1998 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 9641464 Disease Relevance 0.14 Pain Relevance 0.47
Activation of human ECs, obtained from the saphenous vein, with morphine- or anandamide-stimulated NO release (35 nM and 28 nM, respectively) that peaked within 5 min and returned to basal levels within 10 min of agonist stimulation, consistent with constitutive NO synthase (cNOS) activation.
Positive_regulation (activation) of constitutive NO synthase in saphenous vein associated with agonist and morphine
3) Confidence 0.53 Published 1998 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 9641464 Disease Relevance 0.14 Pain Relevance 0.47
These medications are thought to produce a local effect through upregulation and activation of eNOS to increase NO production (Tseng et al 2005).
Positive_regulation (activation) of eNOS
4) Confidence 0.48 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 1.46 Pain Relevance 0.18
The aim of the present study was to determine the mechanism by which aspirin acutely increases the activity of NO synthase type 3 (NOS-3), the predominant NOS isoform expressed by platelets, and specifically whether this occurs through an increase in its acetylation.
Positive_regulation (increases) of NOS-3 in platelets associated with aspirin
5) Confidence 0.47 Published 2009 Journal Cardiovasc. Res. Section Abstract Doc Link 19377066 Disease Relevance 0.10 Pain Relevance 0.23
In the endothelial cell NO will be formed from L-arginine through eNOS activation.
Positive_regulation (activation) of eNOS in endothelial cell
6) Confidence 0.44 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693561 Disease Relevance 0.50 Pain Relevance 0.29
In rodents, both iNOS and eNOS are highly up-regulated in the implantation sites, and NOS inhibitors show synergistic effects with antiprogestins in inhibiting the establishment of pregnancy.
Positive_regulation (up-regulated) of eNOS
7) Confidence 0.42 Published 2000 Journal Hum. Reprod. Section Abstract Doc Link 11041226 Disease Relevance 0.22 Pain Relevance 0.08
In animal models, steady laminar shear stress induces the upregulation of both eNOS and COX-2 [37].
Positive_regulation (induces) of eNOS associated with stress
8) Confidence 0.41 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582806 Disease Relevance 0.49 Pain Relevance 0.54
1-receptor antagonist properties, nebivolol also activates eNOS and may stimulate the expression of eNOS, leading to increased NO production.
Positive_regulation (activates) of eNOS associated with antagonist
9) Confidence 0.41 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582806 Disease Relevance 0.42 Pain Relevance 0.26
Serine phosphorylation of NOS-3 in platelets was decreased, and this was especially marked for serine-1177 phosphorylation, whereas acetylation of NOS-3 was increased, by aspirin incubation.
Positive_regulation (increased) of NOS-3 in platelets
10) Confidence 0.41 Published 2009 Journal Cardiovasc. Res. Section Body Doc Link 19377066 Disease Relevance 0 Pain Relevance 0
Further studies will have to determine whether increasing eNOS activity in humans is associated with coronary collateral development.



Spec (whether) Positive_regulation (increasing) of eNOS
11) Confidence 0.40 Published 2005 Journal BMC Cardiovasc Disord Section Abstract Doc Link PMC1239913 Disease Relevance 0.20 Pain Relevance 0
We hypothesized that a genetic-mediated decreased eNOS activity may limit collateral development in patients with chronic coronary occlusions.


Positive_regulation (mediated) of eNOS associated with coronary heart disease
12) Confidence 0.40 Published 2005 Journal BMC Cardiovasc Disord Section Abstract Doc Link PMC1239913 Disease Relevance 0.26 Pain Relevance 0.05
Further studies will have to determine whether increasing eNOS activity in humans is associated with coronary collateral development.


Spec (whether) Positive_regulation (increasing) of eNOS
13) Confidence 0.40 Published 2005 Journal BMC Cardiovasc Disord Section Body Doc Link PMC1239913 Disease Relevance 0.06 Pain Relevance 0
The following eNOS reaction demonstrates the location of the vulnerable three arms of the eNOS reaction responsible for the generation of eNO.


Positive_regulation (following) of eNOS in arms
14) Confidence 0.40 Published 2003 Journal Cardiovasc Diabetol Section Body Doc Link PMC151667 Disease Relevance 0.67 Pain Relevance 0
Formation of NO could also occur after receptor stimulated activation of constitutive NOS (cNOS) or activation of neuronal NOS (nNOS) in nerve endings.
Positive_regulation (activation) of cNOS in nerve
15) Confidence 0.38 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693561 Disease Relevance 0.50 Pain Relevance 0.29
Important agonists for the activation of the eNOS enzyme (table 7) play an important role in the production of eNO.
Positive_regulation (activation) of eNOS associated with agonist
16) Confidence 0.37 Published 2003 Journal Cardiovasc Diabetol Section Body Doc Link PMC151667 Disease Relevance 1.32 Pain Relevance 0.05
Furthermore, naturally occurring signaling molecules such as morphine, anandamide, interleukin-10 and 17-beta-estradiol appear to exert, in part, their beneficial physiological actions, i.e., immune and endothelial down regulation by the stimulation of cNOS.
Positive_regulation (stimulation) of cNOS associated with morphine
17) Confidence 0.37 Published 2000 Journal Prog. Neurobiol. Section Abstract Doc Link 10739087 Disease Relevance 0 Pain Relevance 0.45
The main tools available to study NOS-dependent effects in humans in vivo have until recently been the nonselective NOS inhibitor l-NMMA and agonists such as acetylcholine that induce eNOS activation.
Positive_regulation (activation) of eNOS associated with agonist
18) Confidence 0.34 Published 2009 Journal Trends in Cardiovascular Medicine Section Body Doc Link PMC2984617 Disease Relevance 0.53 Pain Relevance 0.08
However, Gensh et al. did not observe upregulation of vascular eNOS mRNA
Positive_regulation (upregulation) of eNOS
19) Confidence 0.33 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.30 Pain Relevance 0
is known to decrease eNOS mRNA levels by increasing the rate of mRNA degradation [18,19].
Positive_regulation (increasing) of eNOS
20) Confidence 0.30 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693561 Disease Relevance 1.22 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox